Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenx SE stock logo
ARGX
argenx
$605.38
-0.2%
$605.51
$352.77
$678.21
$36.78B0.6308,853 shs415,834 shs
BioNTech SE stock logo
BNTX
BioNTech
$99.00
-3.3%
$103.82
$76.53
$131.49
$23.76B1.07860,155 shs972,558 shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.24
-2.1%
$31.25
$23.15
$170.47
$10.14B2.237.22 million shs7.02 million shs
Beigene, Ltd. stock logo
ONC
Beigene
$238.84
-1.6%
$246.11
$126.97
$287.88
$23.57B0.49490,433 shs389,533 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenx SE stock logo
ARGX
argenx
+4.38%+10.25%+0.24%-8.90%+60.41%
BioNTech SE stock logo
BNTX
BioNTech
+6.03%+17.88%+2.89%-8.97%+18.34%
Moderna, Inc. stock logo
MRNA
Moderna
+2.29%+4.52%-22.59%-22.23%-74.51%
Beigene, Ltd. stock logo
ONC
Beigene
+5.38%+10.07%-6.34%+24,274,999,900.00%+24,274,999,900.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenx SE stock logo
ARGX
argenx
3.2573 of 5 stars
3.53.00.00.03.31.71.9
BioNTech SE stock logo
BNTX
BioNTech
2.695 of 5 stars
4.42.00.00.03.50.80.0
Moderna, Inc. stock logo
MRNA
Moderna
4.3298 of 5 stars
4.01.00.04.62.82.51.3
Beigene, Ltd. stock logo
ONC
Beigene
2.2987 of 5 stars
3.50.00.00.03.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenx SE stock logo
ARGX
argenx
2.91
Moderate Buy$690.3314.03% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$143.4444.89% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$58.70123.70% Upside
Beigene, Ltd. stock logo
ONC
Beigene
3.00
Buy$316.6732.59% Upside

Current Analyst Ratings Breakdown

Latest MRNA, ARGX, BNTX, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
argenx SE stock logo
ARGX
argenx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00 ➝ $715.00
4/10/2025
Beigene, Ltd. stock logo
ONC
Beigene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$348.00 ➝ $348.00
4/9/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00
4/8/2025
argenx SE stock logo
ARGX
argenx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00 ➝ $720.00
4/7/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$312.00
4/7/2025
Beigene, Ltd. stock logo
ONC
Beigene
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy$312.00
4/1/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/17/2025
argenx SE stock logo
ARGX
argenx
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/13/2025
Beigene, Ltd. stock logo
ONC
Beigene
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$259.00
3/13/2025
BioNTech SE stock logo
BNTX
BioNTech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$145.00
(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenx SE stock logo
ARGX
argenx
$2.19B16.79N/AN/A$69.22 per share8.75
BioNTech SE stock logo
BNTX
BioNTech
$2.75B8.64$4.26 per share23.25$92.17 per share1.07
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.17N/AN/A$28.33 per share0.93
Beigene, Ltd. stock logo
ONC
Beigene
$3.81B6.19N/AN/A$37.10 per share6.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenx SE stock logo
ARGX
argenx
-$295.05M$12.59N/A55.80N/A-2.11%-1.45%-1.29%5/8/2025 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Beigene, Ltd. stock logo
ONC
Beigene
-$881.71M-$6.14N/A336.397.73-25.94%-25.12%-14.95%N/A

Latest MRNA, ARGX, BNTX, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
argenx SE stock logo
ARGX
argenx
$0.98N/AN/AN/A$748.34 millionN/A
5/5/2025Q1 2025
BioNTech SE stock logo
BNTX
BioNTech
-$2.68N/AN/AN/AN/AN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
2/27/2025Q4 2024
argenx SE stock logo
ARGX
argenx
$0.98$1.58+$0.60$11.79$678.52 million$761.22 million
2/27/2025Q4 2024
Beigene, Ltd. stock logo
ONC
Beigene
-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenx SE stock logo
ARGX
argenx
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
$1.531.55%N/AN/A N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Beigene, Ltd. stock logo
ONC
Beigene
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenx SE stock logo
ARGX
argenx
N/A
8.53
7.88
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Beigene, Ltd. stock logo
ONC
Beigene
0.05
1.93
1.72

Institutional Ownership

CompanyInstitutional Ownership
argenx SE stock logo
ARGX
argenx
60.32%
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Beigene, Ltd. stock logo
ONC
Beigene
48.55%

Insider Ownership

CompanyInsider Ownership
argenx SE stock logo
ARGX
argenx
2.43%
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Beigene, Ltd. stock logo
ONC
Beigene
7.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenx SE stock logo
ARGX
argenx
65060.76 million59.29 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080239.97 million193.71 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Beigene, Ltd. stock logo
ONC
Beigene
9,00098.69 million90.59 millionN/A

Recent News About These Companies

Guggenheim Reiterates Buy Rating for Beigene (NASDAQ:ONC)
Reviewing Beigene (ONC) & The Competition
BeiGene receives positive CHMP opinion for Tevimbra

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenx stock logo

argenx NASDAQ:ARGX

$605.38 -1.01 (-0.17%)
Closing price 04:00 PM Eastern
Extended Trading
$595.55 -9.83 (-1.62%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$99.00 -3.34 (-3.26%)
Closing price 04:00 PM Eastern
Extended Trading
$98.98 -0.02 (-0.02%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.24 -0.56 (-2.09%)
Closing price 04:00 PM Eastern
Extended Trading
$25.82 -0.41 (-1.58%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Beigene stock logo

Beigene NASDAQ:ONC

$238.84 -3.91 (-1.61%)
As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.